Literature DB >> 28642301

The specific Bruton tyrosine kinase inhibitor acalabrutinib (ACP-196) shows favorable in vitro activity against chronic lymphocytic leukemia B cells with CD20 antibodies.

Josée Golay1, Greta Ubiali2, Martino Introna2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2017        PMID： 28642301      PMCID： PMC5622871          DOI： 10.3324/haematol.2017.169334

Source DB:  PubMed          Journal:  Haematologica        ISSN： 0390-6078            Impact factor:   9.941


× No keyword cloud information.
  15 in total

1.  Ibrutinib antagonizes rituximab-dependent NK cell-mediated cytotoxicity.

Authors:  Holbrook E Kohrt; Idit Sagiv-Barfi; Sarwish Rafiq; Sarah E M Herman; Jonathon P Butchar; Carolyn Cheney; Xiaoli Zhang; Joseph J Buggy; Natarajan Muthusamy; Ronald Levy; Amy J Johnson; John C Byrd
Journal:  Blood       Date:  2014-03-20       Impact factor: 22.113

2.  Kinase inhibitor ibrutinib to prevent cytokine-release syndrome after anti-CD19 chimeric antigen receptor T cells for B-cell neoplasms.

Authors:  M Ruella; S S Kenderian; O Shestova; M Klichinsky; J J Melenhorst; M A Wasik; S F Lacey; C H June; S Gill
Journal:  Leukemia       Date:  2016-09-28       Impact factor: 11.528

3.  Ibrutinib interferes with the cell-mediated anti-tumor activities of therapeutic CD20 antibodies: implications for combination therapy.

Authors:  Fabio Da Roit; Patrick J Engelberts; Ronald P Taylor; Esther C W Breij; Giuseppe Gritti; Alessandro Rambaldi; Martino Introna; Paul W H I Parren; Frank J Beurskens; Josée Golay
Journal:  Haematologica       Date:  2014-10-24       Impact factor: 9.941

4.  Comparison of Acalabrutinib, A Selective Bruton Tyrosine Kinase Inhibitor, with Ibrutinib in Chronic Lymphocytic Leukemia Cells.

Authors:  Viralkumar Patel; Kumudha Balakrishnan; Elena Bibikova; Mary Ayres; Michael J Keating; William G Wierda; Varsha Gandhi
Journal:  Clin Cancer Res       Date:  2016-12-29       Impact factor: 12.531

5.  Ibrutinib impairs the phagocytosis of rituximab-coated leukemic cells from chronic lymphocytic leukemia patients by human macrophages.

Authors:  Mercedes Borge; María Belén Almejún; Enrique Podaza; Ana Colado; Horacio Fernández Grecco; María Cabrejo; Raimundo F Bezares; Mirta Giordano; Romina Gamberale
Journal:  Haematologica       Date:  2015-01-23       Impact factor: 9.941

6.  Interactions between Ibrutinib and Anti-CD20 Antibodies: Competing Effects on the Outcome of Combination Therapy.

Authors:  Martin Skarzynski; Carsten U Niemann; Yuh Shan Lee; Sabrina Martyr; Irina Maric; Dalia Salem; Maryalice Stetler-Stevenson; Gerald E Marti; Katherine R Calvo; Constance Yuan; Janet Valdez; Susan Soto; Mohammed Z H Farooqui; Sarah E M Herman; Adrian Wiestner
Journal:  Clin Cancer Res       Date:  2015-08-17       Impact factor: 12.531

7.  Glycoengineered CD20 antibody obinutuzumab activates neutrophils and mediates phagocytosis through CD16B more efficiently than rituximab.

Authors:  Josée Golay; Fabio Da Roit; Luca Bologna; Claudia Ferrara; Jeanette H Leusen; Alessandro Rambaldi; Christian Klein; Martino Introna
Journal:  Blood       Date:  2013-10-08       Impact factor: 22.113

8.  Current concepts in the diagnosis and management of cytokine release syndrome.

Authors:  Daniel W Lee; Rebecca Gardner; David L Porter; Chrystal U Louis; Nabil Ahmed; Michael Jensen; Stephan A Grupp; Crystal L Mackall
Journal:  Blood       Date:  2014-05-29       Impact factor: 22.113

9.  Preclinical Evaluation of the Novel BTK Inhibitor Acalabrutinib in Canine Models of B-Cell Non-Hodgkin Lymphoma.

Authors:  Bonnie K Harrington; Heather L Gardner; Raquel Izumi; Ahmed Hamdy; Wayne Rothbaum; Kevin R Coombes; Todd Covey; Allard Kaptein; Michael Gulrajani; Bart Van Lith; Cecile Krejsa; Christopher C Coss; Duncan S Russell; Xiaoli Zhang; Bridget K Urie; Cheryl A London; John C Byrd; Amy J Johnson; William C Kisseberth
Journal:  PLoS One       Date:  2016-07-19       Impact factor: 3.240

Review 10.  Acalabrutinib (ACP-196): a selective second-generation BTK inhibitor.

Authors:  Jingjing Wu; Mingzhi Zhang; Delong Liu
Journal:  J Hematol Oncol       Date:  2016-03-09       Impact factor: 17.388
View more
  15 in total

Review 1.  Pitfalls of Combining Novel Agents in Lymphoma.

Authors:  Thomas D Rodgers; Paul M Barr
Journal:  Curr Treat Options Oncol       Date:  2018-05-28

2.  Acalabrutinib monotherapy in patients with chronic lymphocytic leukemia who are intolerant to ibrutinib.

Authors:  Farrukh T Awan; Anna Schuh; Jennifer R Brown; Richard R Furman; John M Pagel; Peter Hillmen; Deborah M Stephens; Jennifer Woyach; Elena Bibikova; Prista Charuworn; Melanie M Frigault; Ahmed Hamdy; Raquel Izumi; Bolan Linghu; Priti Patel; Min Hui Wang; John C Byrd
Journal:  Blood Adv       Date:  2019-05-14

3.  Acalabrutinib with or without obinutuzumab versus chlorambucil and obinutuzmab for treatment-naive chronic lymphocytic leukaemia (ELEVATE TN): a randomised, controlled, phase 3 trial.

Authors:  Jeff P Sharman; Miklos Egyed; Wojciech Jurczak; Alan Skarbnik; John M Pagel; Ian W Flinn; Manali Kamdar; Talha Munir; Renata Walewska; Gillian Corbett; Laura Maria Fogliatto; Yair Herishanu; Versha Banerji; Steven Coutre; George Follows; Patricia Walker; Karin Karlsson; Paolo Ghia; Ann Janssens; Florence Cymbalista; Jennifer A Woyach; Gilles Salles; William G Wierda; Raquel Izumi; Veerendra Munugalavadla; Priti Patel; Min Hui Wang; Sofia Wong; John C Byrd
Journal:  Lancet       Date:  2020-04-18       Impact factor: 79.321

4.  Chemically-Induced Cross-Linking of Peptidic Fibrils for Scaffolding Polymeric Particles and Macrophages.

Authors:  Jennifer M Armen; Nathan R Schueller; Ketki Y Velankar; Nevil Abraham; Rachelle N Palchesko; Yong Fan; Wilson S Meng; Ellen S Gawalt
Journal:  Macromol Biosci       Date:  2021-01-27       Impact factor: 5.859

5.  Acalabrutinib plus Obinutuzumab in Treatment-Naïve and Relapsed/Refractory Chronic Lymphocytic Leukemia.

Authors:  Jennifer A Woyach; James S Blachly; Kerry A Rogers; Seema A Bhat; Mojgan Jianfar; Gerard Lozanski; David M Weiss; Barbara L Andersen; Michael Gulrajani; Melanie M Frigault; Ahmed Hamdy; Raquel Izumi; Veerendra Munugalavadla; Cheng Quah; Min-Hui Wang; John C Byrd
Journal:  Cancer Discov       Date:  2020-01-08       Impact factor: 38.272

Review 6.  The Impact of Pre-existing Comorbidities and Therapeutic Interventions on COVID-19.

Authors:  Lauren A Callender; Michelle Curran; Stephanie M Bates; Maelle Mairesse; Julia Weigandt; Catherine J Betts
Journal:  Front Immunol       Date:  2020-08-11       Impact factor: 7.561

7.  Evaluation of the Drug-Drug Interaction Potential of Acalabrutinib and Its Active Metabolite, ACP-5862, Using a Physiologically-Based Pharmacokinetic Modeling Approach.

Authors:  Diansong Zhou; Terry Podoll; Yan Xu; Ganesh Moorthy; Karthick Vishwanathan; Joseph Ware; J Greg Slatter; Nidal Al-Huniti
Journal:  CPT Pharmacometrics Syst Pharmacol       Date:  2019-05-12

8.  Sensitive Detection of the Natural Killer Cell-Mediated Cytotoxicity of Anti-CD20 Antibodies and Its Impairment by B-Cell Receptor Pathway Inhibitors.

Authors:  Floyd Hassenrück; Eva Knödgen; Elisa Göckeritz; Safi Hasan Midda; Verena Vondey; Lars Neumann; Sylvia Herter; Christian Klein; Michael Hallek; Günter Krause
Journal:  Biomed Res Int       Date:  2018-03-19       Impact factor: 3.411

Review 9.  First-Line Therapy for Chronic Lymphocytic Leukemia: Bruton Tyrosine Kinase or BCL2 or Both?

Authors:  Hua-Jay J Cherng; Nitin Jain
Journal:  Hematol Oncol Clin North Am       Date:  2021-05-26       Impact factor: 2.861

Review 10.  The regulation and function of CD20: an "enigma" of B-cell biology and targeted therapy.

Authors:  Gabriela Pavlasova; Marek Mraz
Journal:  Haematologica       Date:  2020-06       Impact factor: 11.047
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.